Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Amortization of Deferred Charges: 2013-2024

Historic Amortization of Deferred Charges for Ironwood Pharmaceuticals (IRWD) over the last 12 years, with Dec 2024 value amounting to $1.9 million.

  • Ironwood Pharmaceuticals' Amortization of Deferred Charges rose 19.43% to $418,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 19.80%. This contributed to the annual value of $1.9 million for FY2024, which is 7.57% down from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' Amortization of Deferred Charges is $1.9 million, which was down 7.57% from $2.1 million recorded in FY2023.
  • Ironwood Pharmaceuticals' 5-year Amortization of Deferred Charges high stood at $23.9 million for FY2021, and its period low was $1.9 million during FY2022.
  • For the 3-year period, Ironwood Pharmaceuticals' Amortization of Deferred Charges averaged around $1.9 million, with its median value being $1.9 million (2024).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Amortization of Deferred Charges grew by 13.64% in 2020, and later crashed by 92.26% in 2022.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Amortization of Deferred Charges stood at $22.3 million in 2020, then grew by 7.51% to $23.9 million in 2021, then tumbled by 92.26% to $1.9 million in 2022, then grew by 11.17% to $2.1 million in 2023, then decreased by 7.57% to $1.9 million in 2024.